MEDI CLINICAL’s Post

Overcoming Barriers to Clinical Trial Participation in Oncology Clinical trial participation is critical to advancing oncology research, yet many patients face barriers that prevent their involvement. This insightful article highlights the value of home trial support and robust site networks in addressing these challenges and improving access for diverse patient populations. If you're interested in strategies to enhance patient-centric trial designs and expand participation, I highly recommend giving this a read: https://lnkd.in/e2GFQH7w Let's continue the conversation—what strategies do you think are most effective in making clinical trials more accessible? #ClinicalResearch #Oncology #PatientCentricity #ClinicalTrials

#Expanse #Oncology is integrated within the #Expanse #EHR, keeping care teams in oncology clinics and hospitals on the same page. 🤝🏥 Find out how Major Hospital/Major Health Partners shares information in near-real time, improving the quality of care. 💡🌟https://hubs.ly/Q02YcXFK0 #OncologyCare #DigitalHealth #EHR #CustomerSuccess

In oncology, where research evolves rapidly, staying ahead is crucial. That’s where Living Systematic Reviews (LSRs) come into play. Unlike traditional reviews, LSRs continuously update with new evidence, ensuring that guidelines remain current and relevant. For clinicians, this means informed decision-making that reflects the latest advancements, leading to better patient outcomes. For researchers, LSRs help prioritize studies that address current gaps. And for patients, it means treatments based on the most up-to-date, robust evidence. In a field where lives depend on timely, precise care, LSRs are essential to bridging the gap between new discoveries and clinical practice. This is what Oncoscope-AI does. #Oncology #LivingSystematicReviews #PatientCare #EvidenceBasedMedicine #cancerresearch #OncoScope-AI

Strategy of clinical development in oncology requires global considerations - Tanja Obradovic https://lnkd.in/egMcqj6V #CancerResearch #ClinicalDevelopment #DrugApproval #FDA #Ivonescimab #MultiRegionalClinicalTrials #NSCLC #OncoDaily #Oncology #PatientPopulation #RegulatoryGuidance #Sintilimab #Health #Medicine

Learn actionable steps to improve outcomes through integrative oncology. Enroll today—link in bio. #IntegrativeOncology #HealingJourneys #PatientCare #HolisticHealth #OncologyEducation

Navigating the rapidly evolving treatment landscape of CLL can be challenging for oncology HCPs. With new targeted and immune therapies, tools like @ClinicalCareOptions’ CLL Interactive Treatment Decision Support Tool provide expert case-specific guidance. See how recommendations from CLL experts can impact treatment choices and potentially improve patient care. Check it out and share your experience: https://lnkd.in/ddQt7ynf #CLL #Oncology #HCPTools #PatientCare” https://lnkd.in/d_w9DVqB

Supporting Oncology Patients: Olanzapine Shows Promise in Combating Delayed Chemotherapy-Induced Nausea and Vomiting, CINV. Olanzapine as an effective antiemetic for patients undergoing moderately to highly emetogenic chemotherapy. A randomized, double-blind, placebo-controlled Phase II clinical trial demonstrated olanzapine's efficacy in reducing the incidence and severity of delayed CINV.  These findings underscore the importance of exploring new antiemetic therapies to address both immediate and delayed CINV. Continued research in this area could lead to improved patient outcomes and more comprehensive care strategies.  Learn more about this research in the Comments below. #Oncology #SupportiveCare #CINV #Olanzapine #Antiemetic #ClinicalTrial 

If you work in a digital health, innovation or technology team within #pharma or a #CRO, you might be expanding your involvement with clinical development teams helping to define a program level digital strategy by therapeutic area or asset. I have seen this progress from the early days of Digital Measure pilots to full on "What can we measure that would differentiate our product, improve outcomes faster and define our safety profile?" Join Jaydev Thakkar as he talks about what digital strategies Oncology Clinical Development teams are working on now, especially as it relates to Immuno-Oncology, CAR-T and BiTE Therapies. Learn how remote patient monitoring done in #ClinicalTrials will add value to the label once it is approved and administered to patients in a clinical care setting. This is that "pull through" from clinical to commercial we have been talking about for years in the circles of Digital Measures. I'm so excited to be working at Biofourmis leading product strategy. Come join this webinar and see what we have been up to! Digital Medicine Society (DiMe) DEEP Measures Sean Smith #decentralizedclinicaltrials #DCT #mHealth, #Wearables, #eCOA

Which cancer patient beliefs impact adherence to at-home medications? We've released new findings from our Global Oncology Patient Adherence Study. Learn more including how to optimize #medicationadherence with targeted #patientsupportprograms in our latest article at: https://bit.ly/46seuzJ #patientengagement #behaviorchange

Interesting read 📑 : Amplifying the Patient's Voice in Oncology Early-Phase Clinical Trials: Solutions to Burdens and Barriers American Society of Clinical Oncology (ASCO) #ASCO #patientvoice #patientengagement #clinicaltrials #healthequity #oncology #patientexperience #patient #patientoutcomes #pro #trialdesign